UPI: Promising pancreatic cancer treatment
Media highlights potential new cancer therapy that could be in clinical trials soon
A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans, according to University of Cincinnati researchers.
The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously difficult to treat.
"Based on pre-clinical studies, it has the potential to improve pancreatic cancer treatment," Xiaoyang Qi, PhD, a professor of hematology oncology at the University of Cincinnati College of Medicine and member of the UC Cancer Center. Qi is a lead author on the study which was published in the academic journal Molecular Therapy.
The Cincinnati Enquirer also covered this research.
Featured photo of pancreatic cancer cells courtesy of National Institutes of Health. Credit/Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
Telescope captures information about lonely Jupiter-like gas giant
May 13, 2026
Science outlets highlight a University of Cincinnati student's collaborative discoveries about an exoplanet 901 light years away.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.